|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
GB9119338D0
(en)
|
1991-09-10 |
1991-10-23 |
Inst Of Animal Physiology And |
Control of gene expression
|
|
US5523226A
(en)
*
|
1993-05-14 |
1996-06-04 |
Biotechnology Research And Development Corp. |
Transgenic swine compositions and methods
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US6001349A
(en)
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7001614B2
(en)
|
1996-08-19 |
2006-02-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
US6770291B2
(en)
|
1996-08-30 |
2004-08-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
ATE549918T1
(de)
|
1996-12-03 |
2012-04-15 |
Amgen Fremont Inc |
Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
|
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6749863B1
(en)
|
1997-11-19 |
2004-06-15 |
Georgetown University |
Targeted liposome gene delivery
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
WO2002076196A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transgenic animals expressing antibodies specific for genes of interest and uses thereof
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
EP1575601B1
(en)
|
2002-12-16 |
2015-07-01 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant vaccine viruses expressing il-15 and methods of using the same
|
|
AU2004208031B2
(en)
|
2003-01-28 |
2009-10-08 |
Cellectis |
Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US8218805B2
(en)
|
2003-10-11 |
2012-07-10 |
Charles Hornback |
Wireless speaker system for use with ceiling fans
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
AU2005247950B2
(en)
|
2004-05-27 |
2012-02-02 |
Receptor Logic, Inc. |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
WO2006044962A1
(en)
|
2004-10-19 |
2006-04-27 |
Regeneron Pharmaceuticals, Inc. |
Method for generating an animal homozygous for a genetic modification
|
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
|
WO2007001457A2
(en)
|
2004-11-12 |
2007-01-04 |
Xencor, Inc. |
Antibodies operably linked to selected chemoattractants
|
|
CA2595169A1
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
US7919672B2
(en)
*
|
2005-08-03 |
2011-04-05 |
Therapeutic Human Polyclonals, Inc. |
Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin
|
|
EP1928495A2
(en)
|
2005-08-19 |
2008-06-11 |
Cerus Corporation |
Antibody-mediated enhancement of immune response
|
|
HUE043492T2
(hu)
|
2005-08-23 |
2019-08-28 |
Univ Pennsylvania |
Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
|
|
JP5514539B2
(ja)
|
2006-03-31 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
|
|
CA2688834C
(en)
|
2007-06-01 |
2020-01-07 |
Ronald Buelow |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
|
US7867483B2
(en)
|
2007-10-18 |
2011-01-11 |
Bn Immunotherapeutics, Inc. |
Use of MVA to treat prostate cancer
|
|
US8225343B2
(en)
|
2008-01-11 |
2012-07-17 |
Sony Computer Entertainment America Llc |
Gesture cataloging and recognition
|
|
RU2731084C2
(ru)
*
|
2008-06-27 |
2020-08-28 |
Мерюс Н.В. |
Продуцирующие антитела млекопитающие, не являющиеся человеком
|
|
WO2010039900A2
(en)
|
2008-09-30 |
2010-04-08 |
Aliva Biopharmaceuticals, Inc. |
Non-human mammals for the production of chimeric antibodies
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
CN102638971B
(zh)
|
2009-07-08 |
2015-10-07 |
科马布有限公司 |
动物模型及治疗分子
|
|
RU2425880C2
(ru)
*
|
2009-07-30 |
2011-08-10 |
Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН |
Способ получения трансгенных мышей
|
|
DK2509409T3
(en)
|
2009-12-10 |
2016-11-14 |
Regeneron Pharma |
MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
HRP20151188T4
(hr)
|
2010-02-08 |
2021-10-01 |
Regeneron Pharmaceuticals, Inc. |
Miš sa zajedničkim lakim lancem
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20130185821A1
(en)
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
PL3251503T3
(pl)
|
2010-03-31 |
2024-07-08 |
Ablexis, Llc |
Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
|
|
SI2480675T1
(sl)
|
2010-06-22 |
2016-08-31 |
Regeneron Pharmaceuticals, Inc. |
Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
|
|
RU2580017C2
(ru)
|
2010-07-26 |
2016-04-10 |
Трианни, Инк. |
Трансгенные животные и способы применения
|
|
KR102306967B1
(ko)
|
2010-08-02 |
2021-10-01 |
리제너론 파아마슈티컬스, 인크. |
Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
|
|
LT2738259T
(lt)
|
2011-02-25 |
2020-03-10 |
Regeneron Pharmaceuticals, Inc. |
Adam6 pelės
|
|
JP5893258B2
(ja)
|
2011-03-31 |
2016-03-23 |
フェリカネットワークス株式会社 |
情報処理装置および方法、並びにプログラム
|
|
US20130018582A1
(en)
|
2011-07-13 |
2013-01-17 |
Miller Paul A |
Inertial Navigation Common Azimuth Reference Determination System and Method
|
|
PT3865581T
(pt)
|
2011-08-05 |
2024-10-04 |
Regeneron Pharma |
Murganhos da cadeia leve universal humanizada
|
|
AU2012311286B2
(en)
*
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
KR20140082824A
(ko)
|
2011-10-17 |
2014-07-02 |
리제너론 파아마슈티컬스, 인크. |
제한된 면역글로불린 중쇄 마우스
|
|
RS63220B1
(sr)
|
2011-10-28 |
2022-06-30 |
Regeneron Pharma |
Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
ES2741649T3
(es)
|
2011-10-28 |
2020-02-11 |
Regeneron Pharma |
Ratones con complejo mayor de histocompatibilidad modificado genéticamente
|
|
HUE053444T2
(hu)
|
2011-10-28 |
2021-06-28 |
Regeneron Pharma |
Genetikailag módosított T-sejt receptoros egerek
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
PL2818478T3
(pl)
|
2011-10-28 |
2017-09-29 |
Regeneron Pharmaceuticals, Inc. |
Humanizowane il-6 i receptor il-6
|
|
PL2773671T3
(pl)
|
2011-11-04 |
2022-01-24 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
|
|
US9120662B2
(en)
|
2011-11-14 |
2015-09-01 |
Susan A. Thomson |
Gathering and dispensing scoop with gate valve
|
|
US9547499B2
(en)
|
2011-12-09 |
2017-01-17 |
Microsoft Technology Licensing, Llc |
Device configuration with cached pre-assembled driver state
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
DK2825036T3
(en)
|
2012-03-16 |
2018-07-16 |
Regeneron Pharma |
Histidine engineered light chain antibodies and genetically modified rodents to generate them
|
|
HK1200271A1
(en)
*
|
2012-03-16 |
2015-08-07 |
瑞泽恩制药公司 |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
KR102213535B1
(ko)
|
2012-03-16 |
2021-02-08 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
JP5920830B2
(ja)
|
2012-09-28 |
2016-05-18 |
シスメックス株式会社 |
試料調製装置および細胞分析装置
|
|
SG11201504676VA
(en)
|
2012-12-14 |
2015-07-30 |
Omt Inc |
Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
|
|
CA2900832A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized t-cell co-receptors
|
|
MY185881A
(en)
|
2013-02-20 |
2021-06-14 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
CA2900824A1
(en)
|
2013-02-22 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
|
DK2986729T3
(en)
|
2013-04-16 |
2018-10-29 |
Regeneron Pharma |
TARGETED MODIFICATION OF ROOT THROUGH
|
|
US9783618B2
(en)
*
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
WO2015088643A1
(en)
|
2013-12-11 |
2015-06-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
|
CN106164092A
(zh)
|
2014-03-21 |
2016-11-23 |
瑞泽恩制药公司 |
表现不同结合特征的vl抗原结合蛋白
|
|
CN106255410B
(zh)
|
2014-03-21 |
2020-01-10 |
瑞泽恩制药公司 |
产生单结构域结合蛋白的非人动物
|
|
RU2704283C9
(ru)
|
2014-06-06 |
2020-02-07 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для модификации целевого локуса
|
|
EP3683238A1
(en)
*
|
2014-06-19 |
2020-07-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized programmed cell death 1 gene
|
|
RS60366B1
(sr)
|
2014-06-23 |
2020-07-31 |
Regeneron Pharma |
Sastavljanje dnk posredovano nukleazom
|
|
PT3161128T
(pt)
|
2014-06-26 |
2018-11-21 |
Regeneron Pharma |
Métodos e composições para modificações genéticas alvejadas e métodos de utilização
|
|
KR20170083534A
(ko)
|
2014-09-19 |
2017-07-18 |
리제너론 파마슈티칼스 인코포레이티드 |
키메라 항원 수용체
|
|
RU2732628C2
(ru)
|
2015-04-06 |
2020-09-21 |
Регенерон Фармасьютикалз, Инк. |
Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
|
|
KR102483193B1
(ko)
|
2016-06-03 |
2023-01-04 |
리제너론 파마슈티칼스 인코포레이티드 |
외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
|